… at the 2025 San Antonio Breast Cancer Symposium (SABCS). During the discussion … affect their ability to tolerate breast cancer therapy? What should patients keep … on therapy. Other drugs, like Xeloda (capecitabine), Tukysa (tucatinib), and Herceptin …

… with HER2-positive metastatic breast cancer are living longer, … plus Herceptin and Xeloda or a placebo … 60% of breast cancers, including aggressive triple-negative breast cancers, which … breast cancer are cured? Typically, we treat metastatic breast cancer …

… early or metastatic breast cancer with HER2 alterations, … early breast cancer. In heavily pretreated patients with early breast cancer, … choice of capecitabine [Xeloda; Genentech, Inc] remains … with residual invasive breast cancer following neoadjuvant therapy …

… -positive/HER2-positive metastatic breast cancer, Yuan explained. However, further evidence … , locally recurrent, or metastatic breast cancer? We are looking forward to … trastuzumab emtansine [Kadcyla], and capecitabine [Xeloda]. It used to be the …

… for hormone receptor–positive breast cancer post-CDK4/6 … of approach, like capecitabine [Xeloda] or an antibody-drug … 47;PIK3CA wild-type advanced breast cancer: first results from VIKTORIA … ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) …

… significant issues facing patients with breast cancer, experts told CURE and Dermatology … . These side effects associated with breast cancer treatment can broadly be divided … -specific adverse effects; for example, Xeloda (capecitabine) is known to cause …

… context of breast cancer treatment are acne and rash. Notably, capecitabine (Xeloda) can … toxicities are typical across common breast cancer treatments? Brock: What we would … normally see for patients with breast cancer with adverse events when we …

… HER2-positive advanced/metastatic breast cancer. The DESTINY-Breast12 study … HER2-positive advanced or metastatic breast cancer, regardless of whether they presented … trastuzumab emtansine (Kadcyla), and capecitabine (Xeloda). Yuan concluded that the data …

… (ADCs) for patients with breast cancer. According to Levee, clinical … choice of either capecitabine [Xeloda] or a taxane such … or HER2-ultralow metastatic breast cancer in the second- or … as in the triple-negative breast cancer setting. Ultimately, Levee …

… -positive, endocrine-refractory breast cancer setting, where patients … HR-positive metastatic breast cancer cases without PIK3CA … triple negative breast cancer 315P - SYNERGIA breast cancer - Automated … this with capecitabine [Xeloda], which improved 5- …